
Core Insights - Intelligent Bio Solutions Inc. (INBS) is progressing towards FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System, specifically for opiate codeine, with an anticipated timeline for clearance in the second half of 2026 [2][3] - The company is initiating clinical studies to gather additional data to support its 510(k) submission, with studies expected to conclude in the first half of 2026 [3][4] - INBS's drug testing technology has been adopted by over 450 accounts across 24 countries, indicating a strong global presence and demand for its solutions [4] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, aiming to revolutionize portable testing through fingerprint sweat analysis [5] - The Intelligent Fingerprinting Drug Screening System screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, providing results in under ten minutes [5] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport, logistics, mining, drug treatment organizations, and coroners [5]